Electrochemical biosensors combine the selectivity of electrochemical signal transducers with the specificity of biomolecular recognition strategies. Although they have been broadly studied in different areas of diagnostics, they are not yet fully commercialized. During the COVID-19 pandemic, electrochemical platforms have shown the potential to address significant limitations of conventional diagnostic platforms, including accuracy, affordability, and portability. The advantages of electrochemical platforms make them a strong candidate for rapid point-of-care detection of SARS-CoV-2 infection by targeting not only viral RNA but antigens and antibodies. Herein, we reviewed advancements in electrochemical biosensing platforms towards the detection of SARS-CoV-2 through studying similar viruses. •The complicated nature of conventional tests restricted the availability and distribution of COVID-19 tests.•Electrochemical detection methods can stand as potential rapid tests for the diagnosis of COVID-19.•Electrochemical biosensors combine signal selectivity and molecular specificity for rapid accurate detection of SARS-CoV-2.•The electrochemical biosensors demonstrate trail-blazing sensitivity and specificity, outmatching conventional assays.